Over the past decade, reverse payment settlements between brand-name and generic drug manufacturers has become one of the most controversial topics in the patent-law and health-care communities.
Reverse payment, also known as “pay-for-delay,” occurs when a patent drug owner offers a generic drug company a license or money to delay production of a generic drug for a specified time. This allows the patent owner to maintain longer market control. Although public policy generally encourages settlement, the Federal Trade Commission (FTC) maintains reverse payments are presumptively anticompetitive and cost consumers billions of dollars in increased health-care costs. Meanwhile, the circuit courts disagree over the legality of reverse payments and the standard of law that applies.
Pay-for-Delay
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
